论文部分内容阅读
对22名急性淋巴细胞型白血病患者在第二次缓解或以后的缓解时以及26名急淋患者在他们复发时给予环磷酰胺(每天60mg/kg,连续2天),全身照射920拉德和移植组织相容性抗原(HLA)相同的同胞骨髓,随访至少一年以上,结果因非白血病性原因引起的死亡减低(P=0.07),白血病的复发率也降低(P=0.05),表明对这些患者在缓解期进行骨髓移植能明显提高生存期(P=0.002)。有关急淋化疗预后的因素尚不能说明在缓解期进行骨髓移植与在复发期进行骨髓移植两者复发率的不同,而只有中枢神经系统受累的病史存在与否可能对预后的估计能提供有意义的线索。在缓解期进行骨髓移植的患者所需要的维持治疗和住院时间少于在复发期进行骨髓移植的患者。在缓解期移植的22例患者中有11例,在复发期移植的26例患者中有4例,都在骨髓移植后存活15～35个月。缓解期进行骨髓移植能延长缓解期足以弥补因骨髓移植带来的危险和并发症。有HLA匹配同胞兄弟姐妹的患者骨髓移植应在复发之前进行。
Cyclophosphamide (60 mg / kg daily for 2 consecutive days) was given to 22 acute lymphoblastic leukemia patients on second or subsequent remission and 26 acute lymphoid patients on their recurrence with systemic irradiation of 920 rad and Transplantation of myeloid bone marrow with the same histocompatibility antigen (HLA) followed for at least one year led to a reduction in mortality due to non-leukemia (P = 0.07) and a relapse rate of leukemia (P = 0.05) These patients underwent bone marrow transplantation during remission to significantly improve their survival (P = 0.002). Factors related to the prognosis of acute lymphoid chemotherapy are yet to explain the difference in the rate of relapse between bone marrow transplantation during remission and bone marrow transplantation during relapse, and the presence or absence of a history of central nervous system involvement may provide meaningful prognostic estimates The clues. Patients undergoing bone marrow transplantation during the remission period require less maintenance and hospitalization than those who undergo a bone marrow transplant during the relapse phase. Eleven of the 22 patients transplanted during the remission stage and 4 of 26 patients transplanted during the relapse period survived 15-35 months after the bone marrow transplant. Remission of bone marrow transplantation can prolong the remission sufficient to make up for the risks and complications of bone marrow transplantation. Patients with HLA-matched siblings should undergo bone marrow transplantation prior to recurrence.